Sepracor Ends Xopenex Co-Promotion Deal With Abbott; Estorra Reps Will Detail Pulmonary Agent

A potential mid-year launch of the insomnia therapy will give Sepracor ample time to prepare for the year-end termination of its Xopenex contract with Abbott's Ross division.